Boston

Health

Families are reeling after FDA rejects therapy for kids born without a thymus gland

By Eric Boodman

Biotech

Veritas, genetics company founded by George Church, suspends U.S. operations

By Kate Sheridan

Biotech

Detailed data on Biogen’s resurrected Alzheimer’s drug raise more questions than answers

By Rebecca Robbins and Matthew Herper

Health

Tufts will scour Sackler name from its medical campus, in rebuff of family that controls Purdue Pharma

By Andrew Joseph

Biotech

Sage’s new antidepressant faces major setback in new study

By Matthew Herper and Adam Feuerstein

Biotech

4 questions key to making sense of new data on Biogen’s resurrected Alzheimer’s drug

By Rebecca Robbins

Health Tech

Mayo Clinic taps Boston health tech leader to guide data strategy

By Casey Ross

Pharmalot

As Trump looks overseas for drug pricing ideas, one expert says France has some useful approaches

By Ed Silverman

Biotech

This invite-only club is grooming new biotech CEOs — and helping make them less lonely, too

By Nicholas Florko

Health

Some brain-boosting supplements contain an unapproved drug that could harm users, study warns

By Elizabeth Cooney

Business

Facing bottlenecks in manufacturing cell therapies, Boston leaders plan to build their own

By Sharon Begley

Biotech

Biogen’s top scientist nearly dares FDA not to approve Alzheimer’s drug

By Adam Feuerstein

Biotech

‘The industry has earned it’: Three CEOs own up to biopharma’s bad reputation

By Kate Sheridan

Business

Patient charity settles allegations it helped MS drug makers pay kickbacks

By Elizabeth Cooney

Biotech

FDA approves Alnylam’s Givlaari, second-ever drug based on RNAi

By Kate Sheridan

Politics

Warren and Sanders: More scrutiny needed of commercial boards that decide whether to green-light clinical trials

By Rebecca Robbins

Biotech

First CRISPR treatment for blood diseases shows early benefits in two patients

By Sharon Begley and Adam Feuerstein

Biotech

Novo Nordisk’s parent company to launch research incubator in Boston

By Kate Sheridan

Health

Elizabeth Warren’s health care evolution has earned her friends on the left, but foes in her home state

By Lev Facher — STAT and Liz Goodwin — Boston Globe

Biotech

Alkermes buys Rodin Therapeutics for up to $950 million, giving it possible avenue for growth

By Kate Sheridan

Biotech

A new approach to treating schizophrenia delivers positive results in mid-stage trial

By Adam Feuerstein

Biotech

Roche buying Promedior for $390 million to develop drugs for fibrotic disease

By Jonathan Saltzman — Boston Globe

Biotech

When bio-Twitter greets a sincere thread with snark, what can a Silicon Valley VC say?

By Rebecca Robbins, Damian Garde, and Adam Feuerstein

Pharmalot

Biogen is criticized by the National Multiple Sclerosis Society over pricing for its new pill

By Ed Silverman

Health

Apple launches virtual health studies aiming to enroll hundreds of thousands of customers

By Rebecca Robbins

In tight Massachusetts job market, it’s relo for biotech and remote for tech hires

Merck and Sanofi buy smaller cancer drug firms at big premiums, fueling investor excitement

New data show Bluebird, Bristol CAR-T drug could be pioneering myeloma therapy. Competitors may be close behind

Careful stagecraft at Biogen’s big Alzheimer’s reveal cloaked deep divisions

Families are reeling after FDA rejects therapy for kids born without a thymus gland

Veritas, genetics company founded by George Church, suspends U.S. operations

Detailed data on Biogen’s resurrected Alzheimer’s drug raise more questions than answers

Tufts will scour Sackler name from its medical campus, in rebuff of family that controls Purdue Pharma

Sage’s new antidepressant faces major setback in new study

4 questions key to making sense of new data on Biogen’s resurrected Alzheimer’s drug

Mayo Clinic taps Boston health tech leader to guide data strategy

As Trump looks overseas for drug pricing ideas, one expert says France has some useful approaches

This invite-only club is grooming new biotech CEOs — and helping make them less lonely, too

Some brain-boosting supplements contain an unapproved drug that could harm users, study warns

Facing bottlenecks in manufacturing cell therapies, Boston leaders plan to build their own

Biogen’s top scientist nearly dares FDA not to approve Alzheimer’s drug

‘The industry has earned it’: Three CEOs own up to biopharma’s bad reputation

Patient charity settles allegations it helped MS drug makers pay kickbacks

FDA approves Alnylam’s Givlaari, second-ever drug based on RNAi

Warren and Sanders: More scrutiny needed of commercial boards that decide whether to green-light clinical trials

First CRISPR treatment for blood diseases shows early benefits in two patients

Novo Nordisk’s parent company to launch research incubator in Boston

Elizabeth Warren’s health care evolution has earned her friends on the left, but foes in her home state

Alkermes buys Rodin Therapeutics for up to $950 million, giving it possible avenue for growth

A new approach to treating schizophrenia delivers positive results in mid-stage trial

Roche buying Promedior for $390 million to develop drugs for fibrotic disease

When bio-Twitter greets a sincere thread with snark, what can a Silicon Valley VC say?

Biogen is criticized by the National Multiple Sclerosis Society over pricing for its new pill

Apple launches virtual health studies aiming to enroll hundreds of thousands of customers